Mabqi is a high-tech developer of human therapeutic antibodies. Its phage display core technology platform allows the development of functional antibodies (including pH-sensitive antibodies selected from our oncology-dedicated library) with high developability through proprietary synthetic human libraries. Based on the technical expertise built on more than 20 successful discovery programs (Servier, ADC Therapeutics, … ) and the clinical expertise of its Medical Advisory Board, Mabqi is actively building a portfolio of first-in-class and best-in-class proprietary antibodies with high therapeutic potential in oncology.

Some of these assets are already available for partnered development and licensing opportunities. Mabqi provides also customized discovery services, including full antibody characterization, and has developed a unique and dedicated library to select pH-dependent antibodies for oncology indications.

Thanks to smooth integration of high throughput discovery processes and AI, Mabqi is able to propose a portfolio of outstanding, readily developable antibodies: Tumor Microenvironment Targeting through pH sensitivity, excellent affinity ranges on membrane proteins and biological functionality are combined to offer solutions even in the most complicated cases.

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Montpellier (FRANCE)

–  Employees: 11-50

–  Created in: 2017